Cargando…

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine

BACKGROUND: The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-infection immunity, and post-vaccinated immunity. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huhn, Gregory, Poorbaugh, Josh, Zhang, Lin, Beasley, Stephanie, Nirula, Ajay, Brothers, Jennifer, Welbel, Sharon, Wilson, James, Gillani, Sheena, Weber, Kathleen M., Morack, Ralph, Keckler, Kody, Benschop, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462709/ https://www.ncbi.nlm.nih.gov/pubmed/36083883 http://dx.doi.org/10.1371/journal.pone.0273323

Ejemplares similares

146. Intact Sense of Taste and Smell During COVID-19 Infection Is Associated with Absence of of SARS-CoV-2 Spike Protein Antibody Responses within 3 Months of Symptomatic Illness
por: Wilson, James M, et al.
Publicado: (2021)

The ATEAM study: Advances in technology to enhance PrEP adherence monitoring (ATEAM) among young men who have sex with men
por: Brothers, Jennifer, et al.
Publicado: (2022)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
por: Joseph, Gili, et al.
Publicado: (2023)

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
por: Roca, B, et al.
Publicado: (2021)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Aseptic meningitis after BNT-162b2 COVID-19 vaccination
por: Chan, Amanda CY., et al.
Publicado: (2021)

Reactive arthritis following COVID-19 vaccination with BNT162b2
por: Lebowitz, Emily, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines
por: Lu, Lu, et al.
Publicado: (2022)

Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2021)

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
por: Benschop, Robert J., et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
por: Trimboli, Michele, et al.
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19
por: Hammerman, Ariel, et al.
Publicado: (2022)

BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura
por: Ghosh, A. K., et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
por: Olson, Samantha M., et al.
Publicado: (2022)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
por: Priddy, Frances H., et al.
Publicado: (2022)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
por: Tan, Toh Leong, et al.
Publicado: (2022)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
por: Lam, Chi-Yan, et al.
Publicado: (2023)

Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19
por: Kang, Kyusik, et al.
Publicado: (2022)

Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors
por: Cugno, Massimo, et al.
Publicado: (2021)

COVID-19 infection and BNT162b2 vaccine triggering sarcoid-like lesions in the same patient. Response to: Sarcoid-like reaction in a patient recovering from COVID-19 pneumonia
por: Grieco, Teresa, et al.
Publicado: (2022)

Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19
por: Lozano-Rodríguez, Roberto, et al.
Publicado: (2022)

Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings
por: Granata, Vincenza, et al.
Publicado: (2021)

Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19
por: Bautista García, Javier, et al.
Publicado: (2021)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)
por: Wunderlich, K., et al.
Publicado: (2021)

Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents
por: Oliveira, Carlos R., et al.
Publicado: (2022)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination
por: Lin, Ting-Yu, et al.
Publicado: (2022)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i30ja4uru93q1s74m2rqj2u2n4